| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
mAChR4
|
|---|---|
| ln Vitro |
Emraclidine is an allosteric modulator that is positive for the muscarinic M4 receptor [1].
|
| References |
| Molecular Formula |
C20H21F3N4O
|
|---|---|
| Molecular Weight |
390.402154684067
|
| Exact Mass |
390.166
|
| CAS # |
2170722-84-4
|
| PubChem CID |
140830653
|
| Appearance |
Off-white to light yellow solid powder
|
| LogP |
2.2
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
28
|
| Complexity |
580
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
FC(C1C=C(C=CN=1)N1CC(CC(N2CC3C(=C(C)C=C(C)N=3)C2)=O)C1)(F)F
|
| InChi Key |
DTCZNKWBDTXEBS-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C20H21F3N4O/c1-12-5-13(2)25-17-11-27(10-16(12)17)19(28)6-14-8-26(9-14)15-3-4-24-18(7-15)20(21,22)23/h3-5,7,14H,6,8-11H2,1-2H3
|
| Chemical Name |
1-(2,4-dimethyl-5,7-dihydropyrrolo[3,4-b]pyridin-6-yl)-2-[1-[2-(trifluoromethyl)pyridin-4-yl]azetidin-3-yl]ethanone
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 25 mg/mL (64.04 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (6.40 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (6.40 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.5615 mL | 12.8074 mL | 25.6148 mL | |
| 5 mM | 0.5123 mL | 2.5615 mL | 5.1230 mL | |
| 10 mM | 0.2561 mL | 1.2807 mL | 2.5615 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Link: https://clinicaltrials.gov/ct2/show/NCT07145918
Conditions:SchizophreniaLink: https://clinicaltrials.gov/ct2/show/NCT07219030
Conditions:Healthy VolunteerLink: https://clinicaltrials.gov/ct2/show/NCT05227703
Conditions:Schizophrenia
Title:A Trial of 10 and 30 mg Doses of CVL-231 (Emraclidine) in Participants With Schizophrenia
Status:Completed
updateDate:2025-09-17
Ctid:NCT05227690
Link: https://clinicaltrials.gov/ct2/show/NCT05227690
Conditions:SchizophreniaLink: https://clinicaltrials.gov/ct2/show/NCT05443724
Conditions:SchizophreniaLink: https://clinicaltrials.gov/ct2/show/NCT05644977
Conditions:Healthy Participants|Alzheimer's Disease DementiaLink: https://clinicaltrials.gov/ct2/show/NCT05940402
Conditions:Renal ImpairmentLink: https://clinicaltrials.gov/ct2/show/NCT05935033
Conditions:Hepatic ImpairmentLink: https://clinicaltrials.gov/ct2/show/NCT06366243
Conditions:Healthy ParticipantsLink: https://clinicaltrials.gov/ct2/show/NCT06301971
Conditions:Healthy ParticipantsLink: https://clinicaltrials.gov/ct2/show/NCT05965219
Conditions:Healthy VolunteersLink: https://clinicaltrials.gov/ct2/show/NCT05915546
Conditions:HealthyLink: https://clinicaltrials.gov/ct2/show/NCT04787302
Conditions:SchizophreniaLink: https://clinicaltrials.gov/ct2/show/NCT05245539
Conditions:Blood Pressure|SchizophreniaLink: https://clinicaltrials.gov/ct2/show/NCT04136873
Conditions:SchizophreniaLink: https://clinicaltrials.gov/ct2/show/NCT03217604
Conditions:Healthy VolunteersProducts are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
